Journals / Şişli Etfal Hastanesi Tıp Bülteni / 2009 / Cilt: 43 - Sayı: 2

Comparison of the effect of transdermal and intranasal estrogen treatments on serum hormone and lipid levels and mammographic densities in surgical menopause

Cerrahi menopoz hastalarında transdermal ve intranasal östrojen tedavilerinin serum hormon, lipid değerleri ve mamografik dansite üzerine etkinliklerinin karşılaştırılması

Pages
65–71
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: In our study, both transdermal gel and intranasal spray groups proved to increase serum estradiol levels whereas there was no difference in terms of mammographic densities of the groups according to control group.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: To compare the effects of transdermal estradiol hemihydrate gel and intranasal estradiol hemihyrate spray applications on serum hormone and lipid values and mammographic density in surgical menopause patients.
📊
Key Findings & Data:Material and Method: A total of 58 surgical menopause patients who admitted to Menopause Policlinic in Sisli Etfal Training and Research Hospital Obstetrics and Gyneacology Clinic was included in our study.
💡
Conclusion & Impact:Conclusion: In our study, both transdermal gel and intranasal spray groups proved to increase serum estradiol levels whereas there was no difference in terms of mammographic densities of the groups according to control group.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Lipidler · Menopoz · Mammografi

Abstract

Objective: To compare the effects of transdermal estradiol hemihydrate gel and intranasal estradiol hemihyrate spray applications on serum hormone and lipid values and mammographic density in surgical menopause patients. Material and Method: A total of 58 surgical menopause patients who admitted to Menopause Policlinic in Sisli Etfal Training and Research Hospital Obstetrics and Gyneacology Clinic was included in our study. Patients were divided into three groups: Group 1 (n=20) received Estrava transdermal gel (estradiol hemihydrate 3x0.5 mg/day), group 2 ( n= 20) received intranasal spray (estradiol hemihydrate 2x150µg/ day), group 3 (n= 18) was accepted as the control group. The differences in mammographic densities before and after the treatment of the patients were evaluated according to the Wolfe Scoring System. The serum levels of total cholesterol, HDL, LDL, trigliceride, FSH, LH, E2, TSH, testosterone, cortisole and DHEAS were evaluated at the same time periods. Results: The level of serum estradiol after the treatment in transdermal gel and intranasal spray groups was significantly higher than before the treatment (p= 0.003, p= 0.0001). There was no statistically significant difference in the mammographic densities before and after the treatment in the transdermal gel, intranasal spray and control groups (p>0.05). Conclusion: In our study, both transdermal gel and intranasal spray groups proved to increase serum estradiol levels whereas there was no difference in terms of mammographic densities of the groups according to control group.

Özet

Amaç: Cerrahi menopoz hastalarında, östrojen formlarından transdermal östradiol hemihidrat jel ve intranasal östradiol hemihidrat sprey uygulamalarının serum hormon, lipid değerleri ve mamografik dansite üzerine etkilerinin karşılaştırılması. Gereç ve Yöntem: Çalışmaya Şişli Etfal Eğitim ve Araştırma Hastanesi Kadın Hastalıkları ve Doğum Kliniği menopoz polikliniğine başvuran, cerrahi menopozlu toplam 58 hasta alındı. Hastalar 3 gruba ayrılarak birinci gruba (n=20) Estrava transdermal jel (Östradiol hemihydrate 3x0,5 mg/gün), ikinci gruba (n=20) ise intranazal sprey (Östradiol hemihydrate 2x150 mcg/gün) nasal sprey verildi. Üçüncü grup (n=18) ise kontrol grubu olarak belirlendi. Hastaların tedavi öncesi ve sonrası mamografik dansitelerindeki değişiklikler Wolfe skorlamasına göre değerlendirildi. Total kolesterol, HDL, LDL-kolesterol, trigliserid, FSH, LH, E2, TSH, testosteron, kortizol ve DHEAS düzeyleri de aynı dönemlerde bakıldı. Bulgular: Transdermal jel, intranazal sprey gruplarının, tedavi sonrası E2 değerleri tedavi öncesinden anlamlı olarak yüksek bulundu (p= 0,003, p=0,0001). Transdermal jel, intranazal sprey, kontrol gruplarının tedavi öncesi ve sonrası mamografik dansiteleri arasında, istatistiksel farklılık gözlenmedi (p>0,05). Sonuç: Çalışmamızda transdermal jel ve intranazal spreyin her ikisinin de serum E2 düzeylerini arttırdığı saptanmış, mamografik değerlendirmede her iki grupta da kontrol grubuna göre dansitede anlamlı fark saptanmamıştır.

🔖

Cite This Article

PALAN, A. P., BAKSU, A., ÇELEBİ, Ş., GÜLTEKİN, T., İNCE, Z., GÖKER, N. (2009). Comparison of the effect of transdermal and intranasal estrogen treatments on serum hormone and lipid levels and mammographic densities in surgical menopause. Şişli Etfal Hastanesi Tıp Bülteni, Cilt: 43 - Sayı: 2, 65–71. https://ajindex.com/articles/363490

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Casson PR. Effect of postmenopausal estrogen replacement on circulating androgens. Obstetrics and Gynecology, 90:995-998, 1997
  2. Slater CC, Zhang C, Hodis HN, Mack WJ. Comparison of estrogen and androgen levels after oral estrogen replacement therapy. J Reprod Med, 46:1052-1056, 2001
  3. Aygen EM, Tutuş A, Tayyar M. Medroksiprogesteron ile birlikte verilen konjüge östrojen ve 17 östradiolün seks hormon bağlayıcı globulin, dehidroepiandrostenedion sulfat ve serbest testosteron düzeylerine etkisi. Türk Fertilite Dergisi, 12:80-85, 1998
  4. Andreyko JL, Monroe SE, Marshall LA et al. Concordant supression of serum immuno- reactive LH, FSH and testosterone in postmenopausal women by a potent GnRH antagonist. J Clin Endocrinol Metab, 74:399-405, 1992
  5. Schlegel W, Petersdorf L, Junker R, Schulte H, Ebet C, Eckardstein A. The effects of six months of treatment with a low-dose of conjugated estrogens in menopausal women. Clinical Endocrinology, 51:643-651, 1999
  6. Frye RF, Kroboth PD, Stone RA, Folan M et al. Sex differences in the pharmacokinetics of DHEA after single and multipl dose administration in healthy older adults. J Clin Pharmacol, 40:596-605, 2000
  7. Palacios S. Cancer surveillance during HT. Int J Fertil, 41:340-345, 1996
  8. Sutherland RL, Watts CKW, Musgrove EA. Cell cycle control by steroid hormones in breast cancer: implications for endocrine resistance. Endocr Rel Cancer, 2:87-91, 1995
  9. Yang CP, Daling JR, Band PR, Callagher RP, White E, Weiss NS. Contraceptive hormone use and risk of breast cancer. Cancer Causes and Control, 3:475-479, 1992
  10. Newcomb PA, Longnecker MP, Storer BE, Mittendorf R, Ba¬ron J, Clapp RW, Bogdan C, Willett WC. Long-term hormone replacement therapy and risk of breast cancer in postmenopausal women. Am J Epidemiol, 142:788-795, 1995
  11. Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estro¬gens and progestins and the risk of breast cancer in post me¬nopausal women. N Eng J Med, 332:1589-1593, 1995
  12. Kaufman DW, Palmer JR, de Mouzon J et al: Estrogen repla¬cement therapy and the risk of breast cancer: Results from the Case-Control Surveillance Study. Am J Epidemiol, 134:1375-1385, 1991
  13. Arenas MS, Rodriguez MD, Canteras RR, Cavanillas AB, Vargas RG. Menopausal hormone replacement therapy and breast cancer: A meta-analysis. Obstet Gynecol, 79:286-294, 1992
  14. Writing Group for the Women’s Health Initiative Investigators. Risk and benefits of estrogen plus progestin in healthy postmenopausal w